View in EDS

Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

Saved in:
Bibliographic Details
Title: Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.
Authors: Waddell T; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Pillai M; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Armitage K; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Graham DM; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.; University of Manchester, Manchester, UK., Moran M; Pfizer GmbH, Linkstraße 10, Berlin, 10785, Germany., Dilleen M; Pfizer, Global Product Development, Sandwich, UK., Holmes S; Pfizer Oncology, Surrey, UK., Śleszyńska-Dopiera E; Quanticate, Warsaw, Poland., Hawkins R; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.; University of Manchester, Manchester, UK.
Source: Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (33), pp. 2547-2558. Date of Electronic Publication: 2024 Oct 09.
Publication Type: Clinical Trial; Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39382446
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Waddell+T%22">Waddell T</searchLink>; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Pillai+M%22">Pillai M</searchLink>; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Armitage+K%22">Armitage K</searchLink>; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Graham+DM%22">Graham DM</searchLink>; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.; University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Moran+M%22">Moran M</searchLink>; Pfizer GmbH, Linkstraße 10, Berlin, 10785, Germany.<br /><searchLink fieldCode="AU" term="%22Dilleen+M%22">Dilleen M</searchLink>; Pfizer, Global Product Development, Sandwich, UK.<br /><searchLink fieldCode="AU" term="%22Holmes+S%22">Holmes S</searchLink>; Pfizer Oncology, Surrey, UK.<br /><searchLink fieldCode="AU" term="%22Śleszyńska-Dopiera+E%22">Śleszyńska-Dopiera E</searchLink>; Quanticate, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Hawkins+R%22">Hawkins R</searchLink>; Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.; University of Manchester, Manchester, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2024; Vol. 20 (33), pp. 2547-2558. <i>Date of Electronic Publication: </i>2024 Oct 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39382446
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2024.2385882
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2547
    Titles:
      – TitleFull: Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Waddell T
      – PersonEntity:
          Name:
            NameFull: Pillai M
      – PersonEntity:
          Name:
            NameFull: Armitage K
      – PersonEntity:
          Name:
            NameFull: Graham DM
      – PersonEntity:
          Name:
            NameFull: Moran M
      – PersonEntity:
          Name:
            NameFull: Dilleen M
      – PersonEntity:
          Name:
            NameFull: Holmes S
      – PersonEntity:
          Name:
            NameFull: Śleszyńska-Dopiera E
      – PersonEntity:
          Name:
            NameFull: Hawkins R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 33
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1